

An Observational Study to Evaluate the Role of Dynamic Contrast Enhanced Magnetic Resonance Imaging and Diffusion Weighted Imaging in Evaluation of Ovarian Tumors

Dr. Manish Kumar¹, Dr. Manish Kumar Jha², Dr. Sanjeev Kumar Dwivedi³

¹ Assistant Professor, Department of Radiology, Gouri Devi Institute of Medical Sciences and Hospital, Durgapur, West Bengal, India

² Assistant Professor, Department of Radiology, Gouri Devi Institute of Medical Sciences and Hospital, Durgapur, West Bengal, India

³ Assistant Professor, Department of Radiology, Gouri Devi Institute of Medical Sciences and Hospital, Durgapur, West Bengal, India

Article Info: Received 03 March 2019; Accepted 19 April 2019

Address for Correspondence: Dr. Manish Kumar Jha

Conflict of interest: No conflict of interest.

Abstract

Aim: The aim of the present study was to assess the ability of dynamic contrast-enhanced MRI (DCE–MRI), and Diffusion-weighted image (DWI) to describe uncertain ovarian masses.

Methods: The present study was conducted in the Department of Radiology, Gouri Devi Institute of Medical Sciences and Hospital, Durgapur, West Bengal, India and we did transabdominal ultrasound and transvaginal ultrasound for all cases. We investigated 50 patients with 50 adnexal lesions.

Results: The patients ranged in age from 20 to 78, with a mean of 43.56. Patients worried most about stomach pain and distension. Some cases showed subfertility or abnormal vaginal haemorrhage. Histopathology showed 21 benign, 4 borderline, and 25 malignant tumours. The age range of patients diagnosed with benign tumours was 20–65 years, with a mean age of 39 ± 13 years. However, patients with malignant tumours had an average age of 46 ± 16.953 years, with a mean age of 78 years. The benign tumours included seven serous cystadenoma, six mucinous, three mature cystic teratoma, two ovarian fibromas and fibrothecomas, and one tubo-ovarian abscess. We found four borderline tumors—two serous and two mucinous. The study found 25 invasive malignant masses, including nine serous cyst-adenocarcinomas, six mucinous cysts, three metastatic krukens, three immature teratomas, two fibrosarcomas, and two clear cell carcinomas.

Conclusion: DCE-MRI and DWI have accepted ability to distinguish between benign and malignant ovarian mass.

Keywords: Ovarian, Contrast, Diffusion, MRI

Introduction

Ovarian tumours are a collection of cancerous growths that exhibit a diverse range of characteristics, depending on the exact type of tumour. The various subtypes can be classified into three categories: benign, low-malignant potential/borderline, and malignant.¹⁻³ The classification of ovarian masses based on their histogenetic principles was established by the World Health Organisation (WHO). This classification system distinguishes between ovarian masses originating from coelomic surface epithelial cells (75% of all ovarian neoplasms), germ cells (15-20%), and mesenchyme (the stroma and the sex cord; 5-

10%). Ovarian neoplasms, which typically originate from breast, colon, endometrial, stomach, and cervical malignancies, account for around 5% of metastatic lesions.⁴

Despite being the primary imaging modality for suspected adnexal masses, ultrasonography (US) exhibits limitations in terms of characterisation and staging.⁵ MRI plays a crucial and well-established role in identifying and determining the stage of gynaecological cancer. MRI's exceptional soft tissue resolution enables precise visualisation of tumour dimensions, positioning, spread, and nodal engagement. Although conventional T1 and T2

sequences have been widely used in clinical settings, they are not effective in providing information about the tumour microenvironment. Additionally, they have limitations in evaluating the response of tumours to therapy, especially in distinguishing between residual or recurrent disease and posttreatment fibrosis due to the similarity in their morphological appearances.⁶ The aforementioned differentiation is vital in identifying patients who could potentially get advantages from further salvage treatment alternatives. Functional magnetic resonance imaging (fMRI) has advanced in recent years due to advancements in field strengths, receiver coils, and pulse sequences. This technology has demonstrated its advantages in the detection of brain, breast, and rectal malignancies.⁷ The clinical application of functional magnetic resonance imaging (fMRI) in the context of gynaecological cancer remains unestablished. However, a growing amount of evidence has emerged to substantiate its application in evaluating the response of tumours to therapy, yielding encouraging outcomes thus far, notably in the context of cervical cancer.

MR imaging has demonstrated exceptional precision in identifying and differentiating adnexal masses. Specifically, contrast-enhanced magnetic resonance imaging (MR) can accurately portray the inherent structure of the lesion with exceptional precision.⁸ The diagnostic accuracy of these masses has been improved by the utilisation of dynamic enhanced imaging (DCE-MRI), which possesses the ability to analyse tumour microcirculation and angiogenesis in malignant tumours.^{9,10} The quantitative examination of blood flow and vascular permeability is facilitated by the leakage of contrast media from capillaries into the extravascular extracellular space.¹¹ The utilisation of this technique facilitates the accurate characterisation of the internal structure, demarcation of necrotic regions, identification of solid constituents, examination of papillary projections, septations, and peritoneal implants.¹² The utilisation of this technique is expected to have a significant impact on the assessment of ovarian cancer, since it serves as a predictive and prognostic instrument.¹³ Previous studies investigating the efficacy of Diffusion-weighted imaging (DWI) in the detection of malignant ovarian tumours have yielded

inconclusive results.^{14,15} Subsequent studies have demonstrated the utility of DWI in distinguishing between benign and malignant ovarian masses.^{7,16,17} A subsequent investigation revealed a sensitivity rate of 84% and a specificity rate of 89%.¹⁸

This study aimed to evaluate the efficacy of dynamic contrast-enhanced MRI (DCE-MRI) and Diffusion-weighted imaging (DWI) in accurately describing ovarian masses with unknown characteristics.

MATERIALS AND METHODS

The present study was conducted in the Department of Radiology, Gouri Devi Institute of Medical Sciences and Hospital, Durgapur, West Bengal, India for one year and we did transabdominal ultrasound and transvaginal ultrasound for all cases. We investigated 50 patients with 50 adnexal lesions.

The International Ovarian Tumour Analysis (IOTA) guidelines are employed for the purpose of characterizing ovarian masses. The magnetic resonance (MR) assessment was conducted using a 1.5 T MR equipment. The magnetic resonance imaging (MR) evaluation encompassed T1WI, T2WI, post-contrast fat-suppressed T1WI, and DWI. DWI was conducted at b0, b500, and b1000. A comprehensive analysis was conducted. The MR assessment yielded data pertaining to the average size of the cyst or mass, the ADC value, and the morphological characteristics indicative of malignancy. An individual analysis was conducted to evaluate the diagnostic performance of conventional MRI, DCE-MRI, and DWI in characterizing ovarian masses/cysts. Histopathology is performed on masses following surgical procedures.

Statistical analysis

All statistical calculations were done using SPSS (Statistical Package for the Social Science; SPSS Inc., Chicago, IL, USA) version 22 for Microsoft Windows. Data were statistically described in terms of mean \pm standard deviation (\pm SD) and range, or frequencies (number of cases) and percentages when appropriate. *p* values $< .05$ were considered statistically significant.

RESULTS

Table 1: Patient details

Variables	N%
Complaints	
Abdominal pain	45 (90)
Sub fertility or irregular vaginal bleeding	5 (10)
Histopathology of assessed masses	
Benign	21
Borderline	4
Malignant	25

The patient's age ranged from 20 to 78 years old (mean 43.56 years). The main complaint was abdominal pain and/or abdominal distension; other cases came with different symptoms as subfertility or irregular vaginal bleeding. The histopathology of the assessed masses were 21 benign, 4 borderline, and 25 malignant. The age range for patients with benign tumors was 20 - 65 years (mean 39 ± 13 years) while those with malignant tumors, their age range was 21- 78 years (mean 46 ± 16.953 years).

Table 2: different ADC values of the included masses

	N	ADC Values
Benign n=21		
Serous cystadenoma	7	$1.2 - 2 \times 10^{-3}$ mm ² /sec
Mucinous cysadenoma	6	$1.4 - 2 \times 10^{-3}$ mm ² /sec
Mature cystic teratoma	3	$1.3 - 1.5 \times 10^{-3}$ mm ² /sec
Ovarian fibroma	2	$1.2 - 1.5 \times 10^{-3}$ mm ² /sec
Fibrothecoma	2	$1.6 - 1.8 \times 10^{-3}$ mm ² /sec
Tubo-ovarian abscess	1	1.2×10^{-3} mm ² /sec
Borderline n=4		
Serous	2	1.3×10^{-3} mm ² /sec
Mucinous	2	$1.1 - 1.5 \times 10^{-3}$ mm ² /sec
Malignant n=25		
Serous cyst-adenocarcinoma	9	1.2×10^{-3} mm ² /sec
Mucinous cyst-adenocarcinoma	6	$0.7 - 1 \times 10^{-3}$ mm ² /sec
Metastatic krukenburg	3	0.9×10^{-3} mm ² /sec
Immature teratoma	3	1.2×10^{-3} mm ² /sec
Fibrosarcoma	2	0.9×10^{-3} mm ² /sec
Clear cell carcinoma	2	1.1×10^{-3} mm ² /sec
		$0.8 - 0.9 \times 10^{-3}$ mm ² /sec

Benign masses included seven serous cystadenoma, six mucinous cysadenoma, three mature cystic teratoma, two ovarian fibroma, and fibrothecoma, and one tubo-ovarian abscess. There were four Borderline tumors (two serous and two mucinous). There were 25 invasive malignant masses (Nine Serous cyst-adenocarcinoma, six Mucinous cyst-adenocarcinoma, three Metastatic krukenburg,

three Immature teratoma, two fibrosarcoma, and two clear cell carcinoma). ADC values of malignant tumors showed a minimum of 0.7×10^{-3} mm²/s and a maximum of 1.2×10^{-3} mm²/s. The mean (\pm SD) was 1.01×10^{-3} mm²/s (± 0.34), while ADC values of the benign masses showed a minimum of 1.2×10^{-3} mm²/s and maximum of 2×10^{-3} mm²/s with mean \pm SD 1.6×10^{-3} mm²/s (± 0.27).

Table 3: Analysis of the ovarian lesions size

Dimension	Benign	Borderline	Malignant
Minimum	4.5 cm	6 cm	7 cm
Maximum	15 cm	22 cm	25 cm
Mean \pm SD	9.7 \pm 3.3	14 \pm 7.3	13.7 \pm 5.08

The malignant and borderline ovarian lesions were bigger than the benign lesions.

Table 4: The performance of the preoperative diagnosis

	Ultrasound	Conventional MRI	DCE-MRI	DWI
TP	20	23	24	26
FN	6	3	2	0
FP	6	5	2	1
TN	12	13	16	17
Sensitivity	76.9 %	88.5 %	92.3 %	100 %
Specificity	66.6 %	72.2 %	88.8 %	94.4 %
PPV	76.9 %	82.1 %	85.7 %	96.3 %
NPV	66.6 %	81.2 %	88.8 %	100 %
Accuracy	81.8 %	81.8 %	90.9 %	97.7 %

The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for DWI were 100%, 94.4%, 96.3%, 100%, and 97.7% respectively. The performance of DWI was higher than the conventional MRI and DCE-MRI.

DISCUSSION

MRI plays a crucial and well-established role in identifying and determining the stage of gynaecological cancer. MRI's exceptional soft tissue resolution enables precise visualisation of tumour dimensions, positioning, spread, and nodal engagement. Although conventional T1 and T2 sequences have been widely used in clinical settings, they have certain limitations in assessing tumour microenvironment and evaluating tumour response to therapy. Specifically, they struggle to distinguish between residual or recurrent disease and posttreatment fibrosis due to the similarity in morphological appearances.²⁰ Functional magnetic resonance imaging (fMRI) has advanced in recent years due to advancements in field strengths, receiver coils, and pulse sequences. This technology has demonstrated its advantages in the detection of brain, breast, and rectal malignancies.²¹

The conventional magnetic resonance imaging (MRI) technique evaluates the morphological

characteristics of the lesion, including wall thickening, intra luminal papilla, mural nodules, thick septae, and signal strength on T1WI and T2WI. None of the aforementioned criteria exhibit consistent ability to distinguish between benign and malignant tumours. The advancement of innovative MRI techniques such as DCE MRI and DWI enhances the diagnostic accuracy of MRI.² An individual analysis was conducted to evaluate the diagnostic performance of conventional MRI, DCE-MRI, and DWI in characterising ovarian masses/cysts. The conventional MRI demonstrated a sensitivity of 88.5% and a specificity of 72.2%. This aligns with a meta-analysis examining the efficacy of magnetic resonance imaging (MRI) in the characterization of ovarian masses or cysts in women who have received inconclusive ultrasound evaluations. The sensitivity and specificity were determined to be 76% and 97%, respectively. The DCE-MRI demonstrated a sensitivity of 92.3% and a specificity of 88.8%. In our investigation, this method exhibits a favourable comparison to conventional MRI. The inclusion of DCE in the MRI enhanced the precision of the evaluation. The findings of the systematic review indicate that DCE-MRI exhibits a sensitivity of 81% and specificity of 98%.²² Nevertheless, a more recent study demonstrated a sensitivity of 83% and a

specificity of 75%.²³ The intensity of enhancement was found to be higher in malignant masses compared to benign lesions. The distinction was more pronounced at the initial stage of the contrast research than to the later stage.^{24,25}

The results of our investigation indicate that DWI exhibits a sensitivity of 100%, specificity of 94.4%, PPV of 96.3%, NPV of 100%, and accuracy of 97.7%. DWI exhibited superior performance compared to conventional MRI and DCE-MRI. Our findings indicate that all malignant lesions, with the exception of one case of dermoid cyst, exhibited a strong signal on DWI. This can be attributed to the presence of keratinized material in the dermoid cyst. These findings align with the conclusions found in prior studies. The study demonstrated that the majority of the malignant ovarian masses and a portion of the dermoid cysts had significant intensity on DWI. The majority of benign lesions had a reduced signal strength on DWI.^{26,27}

The study found that the average arterial diffusion coefficient (ADC) values for malignant lesions were $1.01 \pm 10^{-3} \pm 0.34$ mm²/s. The ADC measurements for benign lesions exhibited a mean value of $1.6 \pm 10^{-3} \pm 0.27$ mm² per second. The threshold value we used was 1.2 ± 10^{-3} mm²/s. This aligns with the conclusions drawn by Takeuchi et al. The average ADC value was determined to be 1.03 ± 10^{-3} mm²/s in malignant tumours and 1.38 ± 10^{-3} mm²/s in benign tumours.²⁵ A comprehensive meta-analysis of 16 studies has demonstrated that diffusion-weighted imaging (DWI) exhibits a sensitivity of 91% and specificity of 91% in differentiating between benign and malignant ovarian tumours.²⁸

CONCLUSION

The diagnostic capabilities of DCE-MRI and DWI in differentiating between benign and malignant ovarian masses are widely acknowledged. To present, a significant body of literature has examined the relationship between functional MRI and cervical cancer, yielding encouraging findings. Several studies have demonstrated the additional benefits of functional magnetic resonance imaging (fMRI) in cases of recurrent endometrial and ovarian malignancies. Due to its noninvasive nature, easy accessibility, and absence of ionising radiation, both

DCE-MRI and DWI-MRI offer advantages in tailoring and enhancing patient treatment.

REFERENCES

1. Kurman RJ, Carcangiu ML, Herrington CS. World Health Organisation classification of tumours of the female reproductive organs. International agency for research on cancer; 2014 Feb 3.
2. Foti PV, Attinà G, Spadola S, Caltabiano R, Farina R, Palmucci S, et al. MR imaging of ovarian masses: classification and differential diagnosis. *Insights Imag* 2016;7(1):21–41.
3. Mohaghegh P, Rockall AG. Imaging strategy for early ovarian cancer: characterization of adnexal masses with conventional and advanced imaging techniques. *Radiographics* 2012;32(6):1751–73.
4. Kaku T, Ogawa S, Kawano Y, Ohishi Y, Kobayashi H, Hirakawa T, Nakano H. Histological classification of ovarian cancer. *Medical molecular morphology*. 2003 Mar 1;36(1):9.
5. Valentini AL, Gui B, Miccò M, Mingote MC, De Gaetano AM, Ninivaggi V, Bonomo L. Benign and suspicious ovarian masses—MR imaging criteria for characterization: pictorial review. *Journal of oncology*. 2012 Jan 1;2012.
6. Yamashita Y, Baba T, Baba Y, Nishimura R, Ikeda S, Takahashi M, Ohtake H, Okamura H. Dynamic contrast-enhanced MR imaging of uterine cervical cancer: pharmacokinetic analysis with histopathologic correlation and its importance in predicting the outcome of radiation therapy. *Radiology*. 2000 Sep;216(3):803-9.
7. Punwani S. Contrast enhanced MR imaging of female pelvic cancers: established methods and emerging applications. *European journal of radiology*. 2011 Apr 1;78(1):2-11.
8. Sohaib SA, Reznik RH. MR imaging in ovarian cancer. *Cancer Imaging*. 2007;7(Special issue A):S119.
9. Dogheim OY, Hamid AE, Barakat MS, Eid M, El-Sayed SM. Role of novel magnetic resonance imaging sequences in characterization of ovarian masses. *The Egyptian Journal of Radiology and Nuclear Medicine*. 2014 Mar 1;45(1):237-51.
10. Priest AN, Gill AB, Kataoka M, McLean MA, Joubert I, Graves MJ, Griffiths JR, Crawford RA, Earl H, Brenton JD, Lomas DJ. Dynamic contrast-enhanced MRI in ovarian cancer: Initial

- experience at 3 tesla in primary and metastatic disease. *Magnetic Resonance in Medicine: An Official Journal of the International Society for Magnetic Resonance in Medicine*. 2010 Apr;63(4):1044-9.
11. Andrew N, Andrew B, Masako K, McLean MA, Joubert I, Graves MJ, et al. Dynamic contrast enhanced MRI in ovarian cancer: initial experience in 3 Tesla in primary and metastatic disease. *Magn Reson Med* 2010;63:1044–104.
 12. Young R, Scully R. Sex cord stromal, steroid cell and other ovarian tumors. In: Kurman RJ, editor. *Blaustein pathology of the female genital tract*, vol. 35. New York: Springer Verlag; 2002. p. 905–66.
 13. Vargas HA, Barrett T, Sala E. MRI of ovarian masses. *Journal of Magnetic Resonance Imaging*. 2013 Feb;37(2):265-81.
 14. Fujii S, Kakite S, Nishihara K, Kanasaki Y, Harada T, Kigawa J, Kaminou T, Ogawa T. Diagnostic accuracy of diffusion-weighted imaging in differentiating benign from malignant ovarian lesions. *Journal of Magnetic Resonance Imaging: An Official Journal of the International Society for Magnetic Resonance in Medicine*. 2008 Nov;28(5):1149-56.
 15. Katayama M, Masui T, Kobayashi S, Ito T, Sakahara H, Nozaki A, Kabasawa H. Diffusion-weighted echo planar imaging of ovarian tumors: is it useful to measure apparent diffusion coefficients?. *Journal of computer assisted tomography*. 2002 Mar 1;26(2):250-6.
 16. Mohaghegh P, Rockall AG. Imaging strategy for early ovarian cancer: characterization of adnexal masses with conventional and advanced imaging techniques. *Radiographics*. 2012 Oct;32(6):1751-73.
 17. Thomassin-Naggara I, Daraï E, Cuenod CA, Fournier L, Toussaint I, Marsault C, Bazot M. Contribution of diffusion-weighted MR imaging for predicting benignity of complex adnexal masses. *European radiology*. 2009 Jun;19:1544-52.
 18. Prado JG, Hernando CG, Delgado DV, Martínez RS, Bhosale P, Sanchez JB, Chiva L. Diffusion-weighted magnetic resonance imaging in peritoneal carcinomatosis from suspected ovarian cancer: diagnostic performance in correlation with surgical findings. *European Journal of Radiology*. 2019 Dec 1;121:108696.
 19. Kaijser J, Bourne T, Valentin L, Sayasneh A, Van Holsbeke C, Vergote I, Testa AC, Franchi D, Van Calster B, Timmerman D. Improving strategies for diagnosing ovarian cancer: a summary of the International Ovarian Tumor Analysis (IOTA) studies. *Ultrasound in obstetrics & gynecology*. 2013 Jan;41(1):9-20.
 20. Yamashita Y, Baba T, Baba Y, Nishimura R, Ikeda S, Takahashi M, Ohtake H, Okamura H. Dynamic contrast-enhanced MR imaging of uterine cervical cancer: pharmacokinetic analysis with histopathologic correlation and its importance in predicting the outcome of radiation therapy. *Radiology*. 2000 Sep;216(3):803-9.
 21. Punwani S. Contrast enhanced MR imaging of female pelvic cancers: established methods and emerging applications. *European journal of radiology*. 2011 Apr 1;78(1):2-11.
 22. Iyer VR, Lee SI. MRI, CT, and PET/CT for ovarian cancer detection and adnexal lesion characterization. *American Journal of Roentgenology*. 2010 Feb;194(2):311-21.
 23. Li HM, Qiang JW, Ma FH, Zhao SH. The value of dynamic contrast-enhanced MRI in characterizing complex ovarian tumors. *Journal of ovarian research*. 2017 Dec;10:1-7.
 24. Sohaib SA, Reznik RH. MR imaging in ovarian cancer. *Cancer Imaging*. 2007;7(Special issue A):S119.
 25. Nasr E, Hamed I, Abbas I, Khalifa NM. Dynamic contrast enhanced MRI in correlation with diffusion weighted (DWI) MR for characterization of ovarian masses. *The Egyptian Journal of Radiology and Nuclear Medicine*. 2014 Sep 1;45(3):975-85.
 26. Thomassin-Naggara I, Toussaint I, Perrot N, Rouzier R, Cuenod CA, Bazot M, Daraï E. Characterization of complex adnexal masses: value of adding perfusion-and diffusion-weighted MR imaging to conventional MR imaging. *Radiology*. 2011 Mar;258(3):793-803.
 27. van Nimwegen LW, Mavinkurve-Groothuis AM, de Krijger RR, Hulsker CC, Goverde AJ, Zsiros J, Littooi AS. MR imaging in discriminating between benign and malignant paediatric

ovarian masses: a systematic review. *European radiology*. 2020 Feb;30:1166-81.

28. Pi S, Cao R, Qiang JW, Guo YH. Utility of DWI with quantitative ADC values in ovarian tumors: a

meta-analysis of diagnostic test performance. *Acta Radiologica*. 2018 Nov;59(11):1386-94.